Evaluation of the Safety and Efficacy of ASCA101 in Patients With Advanced Solid Tumors

Summary

This is a prospective, open-label, dose escalation Phase 1 study. The purpose of this study is to evaluate the following objectives in patients with advanced solid tumors after failure of standard of care.

Timeline

Start

2021-11-08

Primary completion

2024-02-29

Completion

2024-02-29

Drugs

Indications